Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsCalendarCompanyFinancialsRevisions 
Financials ($)
Sales 2015 5,14 M
EBIT 2015 1,16 M
Net income 2015 1,08 M
Debt 2015 -
Yield 2015 -
Sales 2016 11,6 M
EBIT 2016 6,71 M
Net income 2016 5,98 M
Debt 2016 -
Yield 2016 -
PER 2015 38,92
PER 2016 6,15
Capi. / Sales 2015 7,21x
Capi. / Sales 2016 3,20x
Capitalization 37,1 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar
11/11Earnings Release
More about the company
Latest news on INTELGENX TECHNOLOGIES COR
07/20 INTELGENX TECHNOLOGIES CORP. : IntelGenx Appoints Andre Godin as New Executive V..
07/20 IntelGenx Appoints Andre Godin as New Executive Vice-President and Chief Fina..
07/20 INTELGENX TECHNOLOGIES : DGAP-News: IntelGenx Appoints Andre Godin as New Execut..
05/15 INTELGENX TECHNOLOGIES : 2015-05-14 IntelGenx Reports Q1, 2015 Results and Provi..
05/14 INTELGENX TECHNOLOGIES : 2015-05-13 IntelGenx Announces Management Changes
05/14 INTELGENX TECHNOLOGIES : Management's Discussion and Analysis of Financial Condi..
05/14 INTELGENX TECHNOLOGIES CORP. : IntelGenx Reports Q1, 2015 Results and Provides C..
05/14 IntelGenx Reports Q1, 2015 Results and Provides Corporate Development Update
More news
Sector news : Generic Pharmaceuticals
06:02a EUROPA-MERGERS : Commission approves acquisition of Hospira by Pfizer, subject t..
05:35a ASTRAZENECA : MedImmune Enters Collaboration With Mirati Therapeutics
04:36a SHIRE : *s&p capital iq cuts shire to 'hold' ('buy') - target 5900 pence
More sector news : Generic Pharmaceuticals
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions